Welcome to the TLDR Biotech newsletter!

Our aim is to be your one-stop source for biotech and pharma updates - all with one daily email.

We’ll likely tweak the exact format and delivery over the next few weeks as we get our feet under us.

So if you have any feedback on what you like (or don’t), we’d love to hear from you!

MINOR HOUSEKEEPING
How these updates are formatted

The newsletter is split into three main sections:

• THE GOOD - good news (eg. fundraises, product approvals)

• THE BAD - negative news (eg. clinical trial failures, layoffs)

• THE UGLY - negative but atypical news (lawsuits, product recalls, scandals)

Within each of the three above parts, there are additional sections for easier navigation:

• Eg. There will be multiple “The Good” sections covering things like Fundraises, Approvals, Partnerships etc.

• There will be also additional tags within these sections (Eg. fundraises may mention Stage, product approvals may mention drug name and disease area.)

See something you want to get into further? Click the Read More (goes out to either a news article or a press release).

THE GOOD
Approvals & Labels

Pfizer, Genmab - FDA grants full approval for cervical cancer ADC
ADC, cancer - Read more

GE Healthcare gets FDA ok for vital sign monitoring
Medical device - Read more

THE GOOD
Clinical Trials

Newron Pharmaceuticals - Phase 2/3 win
Small molecule, schizophrenia - Read more

THE GOOD
Distribution

Biomerica - UAE distribution deal for colorectal and breast cancer screening
Cancer screening - Read more

THE GOOD
Earnings & Finance

Eli Lilly - Raised outlook for GLP-1 only limited by production capacity
Full-year guidance: $42.4-43.6B (raised by $2B)
GLP-1, weight-loss - Read more

Samsung Biologics - Record Q1 earnings via new plant & biosimilars business
Consolidated Sales: Q1 2024 ₩946.9B ($690M) vs Q1 2023 ₩720.9B ($520 million) - 31.3% increase
CDMO, ADC, biosimilar - Read more

THE GOOD
Expansions

Eli Lilly - “the most ambitious expansion plan in our company’s history”
GLP-1, manufacturing capacity - Read more

THE GOOD
Fundraises

General Inception launches Igniter Europe, biotech & life sciences accelerator
Oncology, autoimmune, company building - Read more

Qlaris Bio - $24M Series B
Ophthalmology, small molecule - Read more

Enzala Therapeutics - $100M Series A
Proteins therapeutics - Read more

Daré Bioscience - $22M “Non-Dilutive Strategic Royalty Financing”
Women’s health - Read more

THE GOOD
Mergers & Acquisition, Business Development

Harmony Biosciences buys Epygenix
$35M upfront, $600M biobucks
Epilepsy, small molecule - Read more

Hologic to acquire Endomagnetics, $310M
Women’s health, breast cancer, surgery - Read more

Nuvo Group approaches merger with blank check company
Women’s health, pregnancy, monitoring - Read more

THE GOOD
Partnerships

Novartis expands PeptiDream radioligand discovery partnership
$180M upfront, $2.71B biobucks
Radiopharma, peptides - Read more

THE GOOD
Product Launch

Dornier MedTech launches “UroGPT” for kidney stones
Kidney stones, urology, AI - Read more

Real Chemistry launches GLP-1 analytics platform
AI, Intelligence, GLP-1 - Read more

THE GOOD
Regulatory

FDA seeks public adcomm feedback - Read more

THE GOOD
Reports & Opinions

Novo Nordisk and Eli Lilly’s upcoming obesity drug competition - Read more

THE GOOD
Research

The secret to universal blood donors might be in your guts - Read more

THE BAD
Clinical Trials

NRx Pharmaceuticals Phase 2/3 failure
Small molecule, bipolar depression - Read more

Annovis Bio stock craters on Phase 2/3 endpoint miss
Small molecule, Alzheimer’s - Read more

THE BAD
Corporate Strategy

Walmart shutters in-person and virtual healthcare clinics - Read more

THE BAD
Layoffs

PacBio shuts San Diego site, lays-off 190 employees
Gene sequencing, instruments - Read more

THE BAD
Pipeline Updates

Eli Lilly ditches 3 pipeline assets
Small molecule, gene therapy - Read more

THE UGLY
Cyberattack

UnitedHealth CEO to testify on February ransomware attack
Health tech, cybersecurity - Read more

THE UGLY
Lawsuits

Philips’ $1.1B CPAP settlement - no fault or liability
Medical device - Read more

FTC begins hunting down “junk” pharma patents
Drug Patents - Read more

Despite initial IRA loss, J&J and Bristol Myers Squibb plot appeals
Inflation Reduction Act - Read more

You’re all caught up on the latest Pharma & Biotech News!

We want to hear from you! 📣 

Have comments/questions/complaints about this newsletter?
Send us an email - we want your brutally honest feedback. 📝

And if you like this newsletter and think a friend or colleague would benefit, please share this with them! ♻️